Skip to main content
Top
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Research

The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth

Authors: Caroline Lewis, Marta F Baro, Margarita Marques, Myriam Grüner, Angel Alonso, Ignacio G Bravo

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

The human papillomavirus type 16 E5 protein (HPV16 E5) is 83 amino acids in length and contains three well-defined hydrophobic regions. The protein is expressed at very limited amounts in transfected cells and the absence of specific antibodies has strongly hampered functional analyses. To investigate the relationship between structure and function we have synthesized a codon-adapted version of the gene (hE5) and prepared a series of N-terminal and C-terminal deletions. Immunofluorescence analyses show colocaliation of the protein with calnexin, an ER marker, EEA-1, an early endosomes marker, and Lamp-2, a lysosomal marker. No major colocalization was found between hE5 and the Golgi marker 58 K. Whereas deletions at the C-terminal end of the protein do not greatly alter the localisation pattern, deletion of the first hydrophobic region results in loss of colocalisation with the ER, early endosomes and lysosomes. Further, we show that while the complete E5 protein confers to HaCaT cells the property to grow in an anchorage-independent manner, deletion of the first hydrophobic region results in loss of growth in soft agar. We conclude that the first hydrophobic region of the E5 protein largely determines the biological properties of the viral protein.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bravo IG, Alonso A: Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J Virol 2004, 78: 13613-13626. 10.1128/JVI.78.24.13613-13626.2004PubMedCentralCrossRefPubMed Bravo IG, Alonso A: Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J Virol 2004, 78: 13613-13626. 10.1128/JVI.78.24.13613-13626.2004PubMedCentralCrossRefPubMed
2.
go back to reference Auvinen E, Alonso A, Auvinen P: Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein. Arch Virol 2004, 149: 1745-1759. 10.1007/s00705-004-0325-8CrossRefPubMed Auvinen E, Alonso A, Auvinen P: Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein. Arch Virol 2004, 149: 1745-1759. 10.1007/s00705-004-0325-8CrossRefPubMed
3.
go back to reference Oetke C, Auvinen E, Pawlita M, Alonso A: Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol 2000, 145: 2183-2191. 10.1007/s007050070048CrossRefPubMed Oetke C, Auvinen E, Pawlita M, Alonso A: Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol 2000, 145: 2183-2191. 10.1007/s007050070048CrossRefPubMed
4.
go back to reference Conrad M, Bubb VJ, Schlegel R: The human papillomavirus type 6 and 16 E5 proteins are membrane- associated proteins which associate with the 16- kilodalton pore-forming protein. J Virol 1993, 67: 6170-6178.PubMedCentralPubMed Conrad M, Bubb VJ, Schlegel R: The human papillomavirus type 6 and 16 E5 proteins are membrane- associated proteins which associate with the 16- kilodalton pore-forming protein. J Virol 1993, 67: 6170-6178.PubMedCentralPubMed
5.
go back to reference Bravo IG, Alonso A, Auvinen E: Human papillomavirus type 16 E5 protein. Papillomavirus Rep 2004, 15: 1-6. 10.1179/095741904225004233CrossRef Bravo IG, Alonso A, Auvinen E: Human papillomavirus type 16 E5 protein. Papillomavirus Rep 2004, 15: 1-6. 10.1179/095741904225004233CrossRef
6.
go back to reference Straight SW, Herman B, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995, 69: 3185-3192.PubMedCentralPubMed Straight SW, Herman B, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995, 69: 3185-3192.PubMedCentralPubMed
7.
go back to reference Adam JL, Briggs MW, McCance DJ: A mutagenic analysis of the E5 protein of human papillomavirus type 16 reveals that E5 binding to the vacuolar H+- ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 2000, 272: 315-325. 10.1006/viro.2000.0376CrossRefPubMed Adam JL, Briggs MW, McCance DJ: A mutagenic analysis of the E5 protein of human papillomavirus type 16 reveals that E5 binding to the vacuolar H+- ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 2000, 272: 315-325. 10.1006/viro.2000.0376CrossRefPubMed
8.
go back to reference Rodriguez MI, Finbow ME, Alonso A: Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5- mediated epidermal growth factor receptor overactivation. Oncogene 2000, 19: 3727-3732. 10.1038/sj.onc.1203718CrossRefPubMed Rodriguez MI, Finbow ME, Alonso A: Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5- mediated epidermal growth factor receptor overactivation. Oncogene 2000, 19: 3727-3732. 10.1038/sj.onc.1203718CrossRefPubMed
9.
go back to reference Hwang ES, Nottoli T, Dimaio D: The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995, 211: 227-233. 10.1006/viro.1995.1395CrossRefPubMed Hwang ES, Nottoli T, Dimaio D: The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995, 211: 227-233. 10.1006/viro.1995.1395CrossRefPubMed
10.
go back to reference Conrad M, Goldstein D, Andresson T, Schlegel R: The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. Virology 1994, 200: 796-800. 10.1006/viro.1994.1244CrossRefPubMed Conrad M, Goldstein D, Andresson T, Schlegel R: The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. Virology 1994, 200: 796-800. 10.1006/viro.1994.1244CrossRefPubMed
11.
go back to reference Ashrafi GH, Brown DR, Fife KH, Campo MS: Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 2006, 120: 208-211. 10.1016/j.virusres.2006.02.005CrossRefPubMed Ashrafi GH, Brown DR, Fife KH, Campo MS: Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 2006, 120: 208-211. 10.1016/j.virusres.2006.02.005CrossRefPubMed
12.
go back to reference Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005, 113: 276-283. 10.1002/ijc.20558CrossRefPubMed Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005, 113: 276-283. 10.1002/ijc.20558CrossRefPubMed
13.
go back to reference Ashrafi GH, Haghshenas M, Marchetti B, Campo MS: E5 protein of human papillomavirus 16 down regulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006, 119: 2105-2112. 10.1002/ijc.22089CrossRefPubMed Ashrafi GH, Haghshenas M, Marchetti B, Campo MS: E5 protein of human papillomavirus 16 down regulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006, 119: 2105-2112. 10.1002/ijc.22089CrossRefPubMed
14.
go back to reference Gruener M, Bravo IG, Momburg F, Alonso A, Tomakidi P: The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J 2007, 4: 116. 10.1186/1743-422X-4-116PubMedCentralCrossRefPubMed Gruener M, Bravo IG, Momburg F, Alonso A, Tomakidi P: The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J 2007, 4: 116. 10.1186/1743-422X-4-116PubMedCentralCrossRefPubMed
15.
go back to reference Bravo IG, Crusius K, Alonso A: The E5 protein of human papillomavirus type 16 modulates composition and dynamics of membrane lipids in keratinocyte membranes. Arch Virol 2005, 150: 231-246. 10.1007/s00705-004-0420-xCrossRefPubMed Bravo IG, Crusius K, Alonso A: The E5 protein of human papillomavirus type 16 modulates composition and dynamics of membrane lipids in keratinocyte membranes. Arch Virol 2005, 150: 231-246. 10.1007/s00705-004-0420-xCrossRefPubMed
16.
go back to reference Oelze I, Kartenbeck J, Crusius K, Alonso A: Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J Virol 1995, 69: 4489-4494.PubMedCentralPubMed Oelze I, Kartenbeck J, Crusius K, Alonso A: Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J Virol 1995, 69: 4489-4494.PubMedCentralPubMed
17.
go back to reference Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R: Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003, 311: 105-114. 10.1016/S0042-6822(03)00129-6CrossRefPubMed Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R: Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003, 311: 105-114. 10.1016/S0042-6822(03)00129-6CrossRefPubMed
18.
go back to reference Burkhardt A, Willingham M, Gay C, Jeang KT, Schlegel R: The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology 1989, 170: 334-339. 10.1016/0042-6822(89)90391-7CrossRefPubMed Burkhardt A, Willingham M, Gay C, Jeang KT, Schlegel R: The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. Virology 1989, 170: 334-339. 10.1016/0042-6822(89)90391-7CrossRefPubMed
19.
go back to reference Suprynowicz FA, Disbrow GL, Simic V, Schlegel R: Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16? Virology 2005, 332: 102-113. 10.1016/j.virol.2004.11.011CrossRefPubMed Suprynowicz FA, Disbrow GL, Simic V, Schlegel R: Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16? Virology 2005, 332: 102-113. 10.1016/j.virol.2004.11.011CrossRefPubMed
20.
go back to reference Scholle F, Bendt KM, Raab-Traub N: Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000, 74: 10681-10689. 10.1128/JVI.74.22.10681-10689.2000PubMedCentralCrossRefPubMed Scholle F, Bendt KM, Raab-Traub N: Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000, 74: 10681-10689. 10.1128/JVI.74.22.10681-10689.2000PubMedCentralCrossRefPubMed
21.
go back to reference Mossadegh N, Gissmann L, Müller M, Zentgraf H, Alonso Á, Tomakidi P: Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004, 326: 57-66. 10.1016/j.virol.2004.04.050CrossRefPubMed Mossadegh N, Gissmann L, Müller M, Zentgraf H, Alonso Á, Tomakidi P: Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004, 326: 57-66. 10.1016/j.virol.2004.04.050CrossRefPubMed
22.
go back to reference Samorski R, Gissmann L, Osen W: Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett 2006, 107: 41-49. 10.1016/j.imlet.2006.07.003CrossRefPubMed Samorski R, Gissmann L, Osen W: Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett 2006, 107: 41-49. 10.1016/j.imlet.2006.07.003CrossRefPubMed
23.
go back to reference Cid-Arregui A, Juarez V, Zur HH: A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003, 77: 4928-4937. 10.1128/JVI.77.8.4928-4937.2003PubMedCentralCrossRefPubMed Cid-Arregui A, Juarez V, Zur HH: A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003, 77: 4928-4937. 10.1128/JVI.77.8.4928-4937.2003PubMedCentralCrossRefPubMed
24.
go back to reference Bravo IG, Müller M: Codon usage in papillomavirus genes: practical and fuctional aspects. Papillomavirus Rep 2005, 16: 1-9. 10.1179/095741905X24987CrossRef Bravo IG, Müller M: Codon usage in papillomavirus genes: practical and fuctional aspects. Papillomavirus Rep 2005, 16: 1-9. 10.1179/095741905X24987CrossRef
25.
go back to reference Zhao KN, Liu WJ, Frazer IH: Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Res 2003, 98: 95-104. 10.1016/j.virusres.2003.08.019CrossRefPubMed Zhao KN, Liu WJ, Frazer IH: Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Res 2003, 98: 95-104. 10.1016/j.virusres.2003.08.019CrossRefPubMed
26.
go back to reference Schapiro F, Sparkowski J, Adduci A, Suprynowicz F, Schlegel R, Grinstein S: Golgi alkalinization by the papillomavirus E5 oncoprotein. J Cell Biol 2000, 148: 305-315. 10.1083/jcb.148.2.305PubMedCentralCrossRefPubMed Schapiro F, Sparkowski J, Adduci A, Suprynowicz F, Schlegel R, Grinstein S: Golgi alkalinization by the papillomavirus E5 oncoprotein. J Cell Biol 2000, 148: 305-315. 10.1083/jcb.148.2.305PubMedCentralCrossRefPubMed
27.
go back to reference Maufort JP, Williams SM, Pitot HC, Lambert PF: Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 2007, 67: 6106-6112. 10.1158/0008-5472.CAN-07-0921PubMedCentralCrossRefPubMed Maufort JP, Williams SM, Pitot HC, Lambert PF: Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 2007, 67: 6106-6112. 10.1158/0008-5472.CAN-07-0921PubMedCentralCrossRefPubMed
28.
go back to reference Alonso A, Reed J: Modelling of the human papillomavirus type 16 E5 protein. Biochim Biophys Acta 2002, 1601: 9-18.CrossRefPubMed Alonso A, Reed J: Modelling of the human papillomavirus type 16 E5 protein. Biochim Biophys Acta 2002, 1601: 9-18.CrossRefPubMed
29.
go back to reference Zhang B, Spandau DF, Roman A: E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J Virol 2002, 76: 220-231. 10.1128/JVI.76.1.220-231.2002PubMedCentralCrossRefPubMed Zhang B, Spandau DF, Roman A: E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J Virol 2002, 76: 220-231. 10.1128/JVI.76.1.220-231.2002PubMedCentralCrossRefPubMed
Metadata
Title
The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth
Authors
Caroline Lewis
Marta F Baro
Margarita Marques
Myriam Grüner
Angel Alonso
Ignacio G Bravo
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-30

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.